Key Performance
More- Earnings Score: N/A
- Momentum Score: 32
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
A class action lawsuit has been filed against Fractyl Health, Inc. (NASDAQ: GUTS) alleging that company executives made materially false and misleading statements regarding the effectiveness of its Revita product and the integrity of clinical trial results. The lawsuit covers investors who purchased Fractyl securities between January 13, 2025 and January 29, 2026. The lead plaintiff deadline is October 20, 2026.
09/08/2026, 12:00 PM • GlobeNewswire
A class action lawsuit has been filed against Fractyl Health, Inc. (NASDAQ: GUTS) alleging that company executives made materially false and misleading statements about the effectiveness of its Revita product and the integrity of clinical trial results during the period from January 13, 2025 to January 29, 2026. Investors who purchased Fractyl securities during this period are encouraged to join the lawsuit, with a lead plaintiff deadline of October 20, 2026.
09/03/2026, 12:00 PM • GlobeNewswire
A class action lawsuit has been filed against Fractyl Health, Inc. (NASDAQ: GUTS) alleging that company defendants made materially false and misleading statements regarding Revita's effectiveness and clinical trial integrity during the period from January 13, 2025 to January 29, 2026. Investors who purchased Fractyl securities during this period are encouraged to join the case, with a lead plaintiff deadline of October 20, 2026.
09/01/2026, 12:00 PM • GlobeNewswire
Shareholder class action lawsuits have been filed against GoDaddy Inc., Taboola.com Ltd., and Fractyl Health, Inc., alleging false and misleading statements regarding business practices. Investors who purchased shares during specified periods and experienced losses are encouraged to contact legal counsel. The lead plaintiff deadline is October 20, 2026.
08/26/2026, 7:00 AM • GlobeNewswire
Shareholder class action lawsuits have been filed against Taboola.com Ltd., GoDaddy Inc., and Fractyl Health, Inc., alleging that defendants made false and misleading statements about their business operations. Taboola is specifically accused of overstating publisher relationship values due to increased low-quality publishers. The lead plaintiff deadline for all cases is October 20, 2026.
08/26/2026, 7:00 AM • GlobeNewswire
Shareholder class action lawsuits have been filed against Fractyl Health, GoDaddy, and Taboola, alleging that defendants made false and misleading statements or failed to disclose material adverse facts. The lead plaintiff deadline for all cases is October 20, 2026. Investors who purchased shares during specified periods and experienced losses are encouraged to contact the law firm.
08/26/2026, 7:00 AM • GlobeNewswire
Scalable Biotech Manufacturing Unlocks a $14B Market
The global cell therapy manufacturing market is projected to reach $14 billion by 2035, driven by over 1,000 active clinical candidates. FDA regulatory flexibility is accelerating timelines for cell and gene therapy approvals. Several biotech companies are advancing scalable manufacturing capabilities and clinical programs: Avaí Bio is producing Master Cell Banks for α-Klotho therapy; ImmunityBio validated scalable NK cell manufacturing; Fate Therapeutics achieved outpatient CAR T-cell therapy for autoimmune diseases; Fractyl Health completed pivotal trial randomization for GLP-1 weight maintenance; and Moleculin Biotech enrolled its 45th subject in a Phase 2B/3 AML trial.
03/27/2026, 9:15 AM • Benzinga
Fractyl Health will call its outstanding Tranche A Common Stock Purchase Warrants, allowing holders to exercise at $1.05 per share until December 30, 2025, potentially raising $17.9 million in gross proceeds.
12/15/2025, 5:45 PM • GlobeNewswire
Fractyl Health reported positive 6-month clinical results showing patients maintained stable weight after a single Revita procedure following GLP-1 drug discontinuation, with minimal weight change and promising metabolic control.
12/02/2025, 7:00 AM • GlobeNewswire
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference
Fractyl Health's CEO, Dr. Harith Rajagopalan, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, discussing the company's metabolic therapeutics approach to treating obesity and type 2 diabetes.
12/01/2025, 7:00 AM • GlobeNewswire
Fractyl Health, a metabolic therapeutics company, will report its Q3 2025 financial results and provide business updates on November 12, 2025, focusing on innovative treatments for obesity and type 2 diabetes.
11/05/2025, 7:00 AM • GlobeNewswire
Fractyl Health reported promising clinical trial results showing their Revita procedure maintained weight loss after patients stopped GLP-1 drugs, with treated patients losing 2.5% body weight compared to a 10% weight regain in the control group.
09/26/2025, 7:00 AM • GlobeNewswire
Fractyl Health appointed Christopher Thompson, M.D. and Ian Sheffield to its Board of Directors to strengthen clinical execution and strategic growth in metabolic therapeutics, focusing on obesity and type 2 diabetes treatments.
09/03/2025, 7:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 09/11/2026
Company Profile
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.